iShares美國製藥業ETF IHE 深 滬
等待開盤 05-15 09:30:00 美东时间
89.40
-0.440
-0.49%
華盛通- 最 高89.74
- 今 開89.30
- 成交量 2.58万股
- 最 低 88.92
- 昨 收 89.84
- 總市值 96.11万
- 52周最高 92.0105
- 市盈率 靜 --
- 換手率 239.93%
- 52周最低 62.2713
- 委 比 0.00%
- 總股本 1.08万
- 歷史最高 92.0105
- 量 比 0.46
- 振 幅 0.91%
- 歷史最低 27.8371
- 每 手 1
- 風險率 9.57%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多UnitedHealth Flags Margin Stress, Pushing Investors Toward Broader Healthcare ETFs
UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for diversification.
01-29 01:07
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
01-16 15:30
Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
2025-12-20 04:17
Novo Nordisk's Stock Slump Shows The GLP‑1 Trade's Side Effect: ETF Concentration Risk
Novo's trial setback tests GLP-1-heavy ETFs, highlighting concentration risks while Eli Lilly's diversified pipeline offers relative resilience.
2025-11-25 01:06
Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs
A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.
2025-11-15 22:31
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.
2025-10-31 04:04
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk
The U.S. pharmaceutical industry is at the center of a policy maelstrom.
2025-09-30 00:06
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
2025-09-29 15:20
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
2025-09-08 13:49
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants.
2025-07-26 20:31
